多发性骨髓瘤对首创性pri-miR-17-92抑制剂MIR17PTi的治疗脆弱性
研究开发了靶向MIR17HG初级转录本的LNA gapmeR反义寡核苷酸MIR17PTi,可阻断miR-17-92 miRNA生成。MIR17PTi通过靶向反义活性抑制48种实体瘤和血液肿瘤细胞系增殖,在患者来源骨髓瘤细胞中触发凋亡并诱导MYC依赖性合成致死,在骨髓瘤小鼠模型中显示强体内抗肿瘤活性,在非人灵长类中安全性和药代动力学良好。
要点
- MIR17PTi通过核糖核酸酶H介导降解MIR17HG初级转录本,阻断miR-17-92生成。
- MIR17PTi抑制48种实体瘤和血液肿瘤细胞系增殖,效果优于miR-17-92抑制剂。
- MIR17PTi在骨髓瘤细胞中触发凋亡,诱导MYC依赖性合成致死,体内抗肿瘤活性强。
核心结论
- MIR17PTi是一种新型药理学工具,有待在针对多发性骨髓瘤和其他MYC驱动恶性肿瘤的早期临床试验中测试。
研究设计与样本
- 研究开发了新型LNA gapmeR反义寡核苷酸,诱导核糖核酸酶H介导的MIR17HG初级转录本降解。
- 在48种来自实体瘤和血液肿瘤的癌细胞系中评估先导LNA ASO MIR17PTi的增殖抑制作用。
- 在患者来源的多发性骨髓瘤细胞中研究MIR17PTi的作用机制。
- 在携带临床相关多发性骨髓瘤模型的非肥胖糖尿病重症联合免疫缺陷小鼠中评估体内抗肿瘤活性。
- 在非人灵长类中评估安全性和药代动力学特征。
主要发现
- MIR17PTi通过靶向反义活性抑制48种癌细胞系增殖,效果优于miR-17-92抑制剂。
- MIR17PTi通过损害稳态MYC/miR-17-92前馈环路,在患者来源多发性骨髓瘤细胞中触发凋亡并诱导MYC依赖性合成致死。
- 以BIM为中心的前馈环路改变对MIR17PTi诱导多发性骨髓瘤细胞毒性起关键作用。
- MIR17PTi在携带临床相关多发性骨髓瘤模型的非肥胖糖尿病重症联合免疫缺陷小鼠中表现出强体内抗肿瘤活性。
- MIR17PTi在非人灵长类中具有有利的安全性和药代动力学特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The microRNA (miRNA) cluster miR-17-92 is oncogenic and represents a valuable therapeutic target in c-MYC (MYC)-driven malignancies. Here, we developed novel LNA gapmeR antisense oligonucleotides (ASOs) to induce ribonuclease H-mediated degradation of MIR17HG primary transcripts and consequently prevent biogenesis of miR-17-92 miRNAs (miR-17-92s). The leading LNA ASO, MIR17PTi, impaired proliferation of several cancer cell lines (n = 48) established from both solid and hematologic tumors by on-target antisense activity, more effectively as compared with miR-17-92 inhibitors. By focusing on multiple myeloma (MM), we found that MIR17PTi triggers apoptosis via impairment of homeostatic MYC/miR-17-92 feed-forward loops (FFLs) in patient-derived MM cells and induces MYC-dependent synthetic lethality. We show that alteration of a BIM-centered FFL is instrumental for MIR17PTi to induce cytotoxicity in MM cells. MIR17PTi exerts strong in vivo antitumor activity in nonobese diabetic severe combined immunodeficient mice bearing clinically relevant models of MM, with advantageous safety and pharmacokinetic profiles in nonhuman primates. Altogether, MIR17PTi is a novel pharmacological tool to be tested in early-phase clinical trials against MM and other MYC-driven malignancies.
引用
- Morelli E, Biamonte L, Federico C, et al. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018. PMID: 29997223. doi:10.1182/blood-2018-03-836601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。